A Phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma

Cancer

Volumn 79, Issue 4, 1997, Pages 730-739

  Buzdar, Aman U ^a   Jones, Stephen E ^b   Vogel, Charles L ^c   Wolter, Janet ^d   Plourde, Paul ^e   Webster, Alan ^e  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^c Parkway Regional Medical Center   (United States)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

^e ASTRAZENECA   (United Kingdom)

Author keywords

anastrozole; aromatase inhibition; breast carcinoma; megestrol acetate; postmenopausal; progestin

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; MEGESTROL ACETATE; TAMOXIFEN; TAMOXIFEN CITRATE;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER HORMONE THERAPY; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; DRUG TOLERABILITY; EDEMA; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; WEIGHT GAIN;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CARCINOMA; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FEMALE; HUMANS; MEGESTROL ACETATE; MIDDLE AGED; NITRILES; POSTMENOPAUSE; PREGNANES; TRIAZOLES;

EID: 0031054095     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970215)79:4<730::AID-CNCR10>3.0.CO;2-0     Document Type: Article

References (26)

1. Mouridsen H, Palshof T, Patterson J, et al. Tamoxifen in advanced breast cancer. Cancer Treat Rev 1978;5:131-41.
2. Henderson IC. Endocrine therapy in metastatic breast cancer. In: Harris JR, Hellman S, Henderson IC, Kinne DW, editors. Breast diseases. 2nd edition. Philadelphia: J.B. Lippincott Company, 1991:419-22.
3. Lipton A, Harvey HA, Santen RJ, et al. Randomised trial of aminoglutethimide versus tamoxifen in metastatic breast cancer. Cancer Res 1982;42:3434-6.
4. Coombes RC, Powles TJ, Easton D, et al. Adjuvant aminoglutethimide therapy for postmenopausal patients with primary breast cancer. Cancer Res 1987;47:2496-9.
5. Henderson C, Hayes DF, Come S, Harris JR, Canellos G. New agents and new medical treatments for advanced breast cancer. Semin Oncol 1987;14:34-64.
6. Miller WR. Aromatase inhibitors-where are we now? Br J Cancer 1996;73:415-7.
7. Plourde PV, Dyroff M, Dukes M. Arimidex: a potent and selective fourth-generation aromatase inhibitor. Breast Cancer Res Treat 1994;30:103-11.
8. Hayward JL, Carbone PP, Heuson J-C, et al. Assessment of response to therapy in advanced breast cancer. Eur J Cancer 1977;13:89-94.
9. de Haes JCJM, van Knippenberg FCE, Neijt JP. Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist. Br J Cancer 1992;66:402-4.
10. Jonat W, Howell A, Blomqvist C, et al. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer 1996;32A:404-12.
11. Buzdar A, Jonat W, Howell A, et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two Phase III trials. J Clin Oncol 1996;7:2000-11.
12. Buzdar AU, Smith R, Vogel C, et al. Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: results of two randomized double-blind controlled multiinstitutional trials. Cancer 1996;77:2503-11.
13. Gill PG, Gebski V, Snyder R, et al. Randomized comparison of the effects of tamoxifen, megestrol acetate, or tamoxifen plus megestrol acetate on treatment response and survival in patients with metastatic breast cancer. Ann Oncol 1993;4:741-4.
14. Ingle JN, Ahmann DL, Green SJ, et al. Randomised clinical trial of megestrol acetate versus tamoxifen in paramenopausal or castrated women with advanced breast cancer. Am J Clin Oncol 1982;5:155-60.
15. Morgan LR. Megestrol acetate vs. tamoxifen in advanced breast cancer in postmenopausal patients. Semin Oncol 1985;12:43-7.
16. Muss HB, Case LD, Capizzi RL, et al. High-versus standard-dose megestrol acetate in women with advanced breast cancer: a Phase III trial of the Piedmont Oncology Association. J Clin Oncol 1990;8:1797-1805.
17. Mercer PM, Ebbs SR, Fraser SCA, et al. Trial of aminoglutethimide vs hydrocortisone as second-line hormone treatment of advanced breast cancer. Eur J Surg Oncol 1993;19:254-8.
18. Pronzato P, Rubagotti A, Amoroso D, et al. Second-line hormonotherapy for breast cancer. Usefulness of first-line continuation. Am J Clin Oncol 1993;16:522-5.
19. Ingle JN, Green SJ, Ahmann DL, et al. Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer. J Clin Oncol 1986;4:958-64.
20. Howell A, Mackintosh J, Jones M, et al. The definition of the 'no change' category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast. Eur J Cancer Clin Oncol 1988;24:1567-72.
21. Robertson JFR, Williams MR, Todd J, et al. Factors predicting the response of patients with advanced breast cancer to endocrine (Megace) therapy. Eur J Cancer Clin Oncol 1989;23:469-75.
22. Dixon AR, Jackson L, Chan S, et al. A randomized trial of second-line hormone vs single agent chemotherapy in tamoxifen resistant breast cancer. Br J Cancer 1992;66:402-4.
23. Congdon J, Green S, O'Sullivan J, et al for the Southwest Oncology Group. Megestrol acetate (MA) and Aminoglutethimide/Hydrocortisone (Ag/HC) in sequence or combination as second-line endocrine therapy of oestrogen receptor positive metastatic breast cancer [abstract 45]. Proc Am Soc Clin Oncol 1991;10:93.
24. Loprinzi CL, Ellison NM, Schaid DJ, et al. Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer lnst 1990;82:1127-32.
25. Von Roenn JH, Armstrong D, Kolter DP, et al. Megestrol acetate in patients with AIDS-related cachexia. Ann Intern Med 1994;121:393-9.
26. Patterson AHG, Hanson J, Prichard K, et al. Comparison of antiestrogen and progesterone therapy for initial treatment and consequences of their combination for second-line treatment of recurrent breast cancer. Semin Oncol 1990;17:52-62.